Asset Details
Do you wish to reserve the book?
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer
Do you wish to request the book?
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer
2026
Overview
The rapid development of novel endocrine therapies (ETs), such as selective estrogen receptor degraders (SERDs), proteolysis targeting chimeras (PROTACs), selective estrogen receptor covalent antagonists (SERCAs), and complete estrogen receptor antagonists (CERANs) has generated enthusiasm for their use in earlier treatment lines in advanced estrogen receptor-positive (ER+) human epidermal receptor 2-negative (HER2-) breast cancer (BC). Multiple phase III trials have demonstrated progression-free survival (PFS) benefit for novel ETs, especially in patients harboring
ESR1
mutations. However, their broader use may be limited by toxicity concerns, adherence challenges, need for combination therapy, and financial burden. In this manuscript, we provide a concise review of key clinical trial outcomes for novel ETs with a focus on SERDs and critically evaluate their use in earlier lines of therapy. We also examine the design of ongoing adjuvant and first-line trials and explore the clinical implications of circulating tumor DNA (ctDNA)-guided treatment strategies.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
